Dapagliflozin effective in treating type 1 diabetes - Video

Published On 2022-02-26T17:42:46+05:30 | Updated On 26 Feb 2022 5:42 PM IST

Overview

Type 1 diabetes is a worrying condition as ones immune system destroys insulin-making cells in the pancreas. Recent data published in PLOS One supports the preventive and protective role of SGLT2 inhibitors in cardiovascular disease (CVD) associated with type 1 diabetes.

The study provides experimental data for SGLT2i dapagliflozin's (DAPA) cardioprotective effect in T1D. Results showed that DAPA prevents cardiac inflammation, fibrosis, and intimal thickening. This suggests that SGLT2i may provide a novel therapeutic opportunity for hindering the development of CVD in type 1 diabetes, thereby improving the outcomes.

For more information check out the full story on the link below:

SGLT2 Inhibitor Dapagliflozin May Prevent Cardiovascular Complications In Type 1 Diabetes: Study

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751